Aclarion, Inc., a pioneer in healthcare technology focused on chronic low back pain diagnostics, has unveiled plans for a registered direct offering of its common stock. The offering, priced at $9.25 per share, aims to sell 506,803 shares, potentially raising around $4.7 million. This financial move is set to conclude by January 31, 2025, marking a significant step in the company's growth trajectory.
The proceeds from this offering are earmarked for several strategic areas crucial to Aclarion's mission. These include expanding market presence, generating clinical evidence, advancing product development, enhancing quality measures, and supporting general corporate functions. Dawson James Securities, Inc. has been appointed as the sole placement agent for this transaction, which operates under a shelf registration statement effective since September 23, 2024, by the Securities and Exchange Commission.
At the heart of Aclarion's innovation is the Nociscan platform, a cloud-based software solution that leverages Magnetic Resonance Spectroscopy, proprietary signal processing, and augmented intelligence algorithms. This technology aids physicians in pinpointing the origins of chronic low back pain by analyzing chemical biomarkers from MRI data, offering a pathway to more personalized and effective treatment plans.
It's important to note that this announcement does not serve as an offer to sell securities. Interested parties are directed to consult the prospectus supplement to be filed with the SEC for detailed information regarding the offering and its inherent risks. This development underscores Aclarion's commitment to revolutionizing chronic pain diagnostics and treatment, with potential implications for healthcare providers, patients, and the broader medical technology industry.
